Besides expertise in medicines and pharmaceutical policies, the Pharmacoeconomics Department has also been for long involved in the activities related to medical devices.
Medical devices include a variety of medical technologies and procedures such as syringes, pacemakers, wheelchairs. In order to improve market surveillance in this area, the Medical Devices Act regulates that Austria has to keep its own register for medical devices as well as a register for testing, monitoring and certification bodies.
Austrian Register of Medical Devices
Gesundheit Österreich GmbH was commissioned in 2001 by the then Austrian Federal Ministry of Health to set up and maintain these registers. Since January 2002, the registration of medical devices and in-vitro diagnostics has only been possible on the website www.medizinprodukteregister.at and carried out by all companies or persons subject to registration in the form of a free self-registration.
For further information: see Austrian Register of Medical Devices (in German)
European Database for Medical Devices (EUDAMED)
GÖG, together with the Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection, acts as the national contact point for the European Database for Medical Devices (EUDAMED) and has been transmitting the Austrian data to the European database since May 2011. This allows a quick exchange of information between EU Member States, and it will be able to respond quickly to the safety risks of medical devices.
More recently, the Pharmacoeconomics Department has been working on policy-related aspects of medical devices, in particular prices and policies for pricing and reimbursement of medical devices.
A sub-group of the PPRI network on medical devices was established in 2018.
Value DX - https://value-dx.eu/
GÖG is a partner in EU project to fight antimicrobial resistance through diagnostics.
Policy options for antibiotics and diagnostics in the field of AMR (anti microbial resistance)
Gesundheit Österreich was commissioned by the Global AMR R&D Hub to conduct two “trans-national studies to inform national policy maker options in addressing novel antibiotic and diagnostic reimbursement and purchasing”. The studies aim to provide evidence on policy options for antibiotics and diagnostics in the field of Antimicrobial Resistance (AMR), which has become a complex issue of major global concern. In particular, the studies aim to identify and assess policy options which can incentivise producers to invest in the development of novel antibiotics and diagnostics and thus contribute to ensuring resistant infections remain treatable for all patients. The studies will look into areas of highest unmet need and focus on the pricing and reimbursement as well as on procurement mechanisms in ten selected countries across the globe.